<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2205233681
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ticagrelor SPC F.C. Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TICAGRELOR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        83.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC24
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ticagrelor SPC in combination with acetylsalicylic acid (another antiplatelet agent) is to be used in adults only. You have been given this medicine because you have had:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a heart attack, or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unstable angina (angina or chest pain that is not well controlled).</p><p>It reduces the chances of you having another heart attack, stroke or dying from a disease related to your heart or blood vessels.</p><p>How Ticagrelor SPC works</p><p>Ticagrelor SPC affects cells called &lsquo;platelets&rsquo; (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to plug tiny holes in blood vessels that are cut or damaged. However, platelets can also form clots inside diseased blood vessels in the heart and brain. This can be very dangerous because:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the clot can cut off the blood supply completely; this can cause a heart attack (myocardial infarction) or stroke, or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the clot can partly block the blood vessels to the heart; this reduces the blood flow to the heart and can cause chest pain which comes and goes (called &lsquo;unstable angina&rsquo;).</p><p>Ticagrelor SPC helps stop the clumping of platelets. This reduces the chance of a blood clot forming that can reduce blood flow.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ticagrelor SPC if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to ticagrelor or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are bleeding now.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a stroke caused by bleeding in the brain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are taking any of the following medicines:</p><p>-&nbsp;&nbsp; ketoconazole (used to treat fungal infections)</p><p>-&nbsp;&nbsp; clarithromycin (used to treat bacterial infections)</p><p>-&nbsp;&nbsp; nefazodone (an antidepressant)</p><p>-&nbsp;&nbsp; ritonavir and atazanavir (used to treat HIV infection and AIDS)</p><p>Do not take Ticagrelor SPC if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Ticagrelor SPC if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have an increased risk of bleeding because of:</p><p>-&nbsp; a recent serious injury</p><p>-&nbsp; recent surgery (including dental work, ask your dentist about this)</p><p>-&nbsp; you have a condition that affects blood clotting</p><p>-&nbsp; recent bleeding from your stomach or gut (such as a stomach ulcer or colon &lsquo;polyps&rsquo;)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You are due to have surgery (including dental work) at any time while taking Ticagrelor SPC.</p><p>This is</p><p>because of the increased risk of bleeding. Your doctor may want you to stop taking this medicine 5 days prior to surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your heart rate is abnormally low (usually lower than 60 beats per minute) and you do not already have in place a device that paces your heart (pacemaker).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have asthma or other lung problems or breathing difficulties.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have had any problems with your liver or have previously had any disease which may have affected your liver.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You have had a blood test that showed more than the usual amount of uric acid</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.</p><p>If you are taking both Ticagrelor SPC and heparin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may require a sample of your blood for diagnostic tests if they suspect a rare platelet disorder caused by heparin. It is important that you inform your doctor that you are taking both Ticagrelor SPC and heparin. as Ticagrelor SPC may affect the diagnostic test.</p><p>Children and adolescents</p><p>Ticagrelor SPC is not recommended for children and adolescents under 18 years.</p><p>Other medicines and Ticagrelor</p><p>Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Ticagrelor SPC can affect the way some medicines work and some medicines can have an effect on Ticagrelor SPC.</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more than 40 mg daily of either simvastatin or lovastatin (medicines used to treat high cholesterol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (an antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine and phenobarbital (used to control seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin (used to treat heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine (used to lessen your body&rsquo;s defenses)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine and diltiazem (used to treat abnormal heart rhythms)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta blockers and verapamil (used to treat high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; morphine and other opioids (used to treat severe pain)</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase your risk of bleeding:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;oral anticoagulants&rsquo; often referred to as ʽblood thinners&rsquo; which include warfarin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Steroidal Anti-Inflammatory Drugs (abbreviated as NSAIDs) often taken as painkillers such as ibuprofen and naproxen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selective Serotonin Reuptake Inhibitors (abbreviated as SSRIs) taken as antidepressants such as paroxetine, sertraline and citalopram</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat heartburn), ergot alkaloids (used to treat migraines and headaches).</p><p>Also tell your doctor that because you are taking Ticagrelor SPC, you may have an increased risk of bleeding if your doctor gives you fibrinolytics, often called &lsquo;clot dissolvers&rsquo;, such as streptokinase or alteplase.</p><p>Pregnancy and breast-feeding</p><p>It is not recommended to use Ticagrelor SPC if you are pregnant or may become pregnant. Women should use appropriate contraceptive measures to avoid pregnancy while taking this medicine.</p><p>Talk to your doctor before taking this medicine if you are breast-feeding. Your doctor will discuss with you the benefits and risks of taking Ticagrelor SPC during this time.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Driving and using machines</p><p>Ticagrelor SPC is not likely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medicine, be careful while driving or using machines.</p><p>Sodium content</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say it is essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much to take</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is two tablets at the same time (loading dose of 180 mg). This dose will usually be given to you in the hospital.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After this starting dose, the usual dose is one tablet of 90 mg twice a day for up to 12 months unless your doctor tells you differently.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine around the same time every day (for example, one tablet in the morning and one in the evening).</p><p>Taking Ticagrelor SPC with other medicines for blood clotting</p><p>Your doctor will usually also tell you to take acetylsalicylic acid. This is a substance present in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75-150 mg daily).</p><p>How to take Ticagrelor SPC</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the tablet with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can check when you last took a tablet of Ticagrelor SPC by looking on the blister. There is a sun (for the morning) and a moon (for the evening). This will tell you whether you have taken the dose.</p><p>If you have trouble swallowing the tablet</p><p>If you have trouble swallowing the tablet you can crush it and mix with water as follows:</p><p>&middot;&nbsp;&nbsp; Crush the tablet to a fine powder.</p><p>&middot;&nbsp;&nbsp; Pour the powder into half a glass of water.</p><p>&middot;&nbsp;&nbsp; Stir and drink immediately.</p><p>&middot;&nbsp;&nbsp; To make sure there is no medicine left, rinse the empty glass with another half a glass of water and drink it.</p><p>If you are in the hospital you may be given this tablet mixed with some water and given through a tube via the nose (nasogastric tube).</p><p>If you take more Ticagrelor SPC than you should</p><p>If you take more Ticagrelor SPC than you should, talk to a doctor or go to hospital straight away. Take the medicine pack with you. You may be at increased risk of bleeding.</p><p>If you forget to take Ticagrelor SPC</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, just take your next dose as normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose (two doses at the same time) to make up for the forgotten dose.</p><p>If you stop taking Ticagrelor SPC</p><p>Do not stop taking Ticagrelor SPC without talking to your doctor. Take this medicine on a regular basis and for as long as your doctor keeps prescribing it. If you stop taking Ticagrelor SPC, it may increase your chances of having another heart attack or stroke or dying from a disease related to your heart or blood vessels.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Ticagrelor SPC affects blood clotting, so most side effects are related to bleeding. Bleeding may occur in any part of the body. Some bleeding is common (like bruising and nosebleeds). Severe bleeding is uncommon, but can be life threatening.</p><p>See a doctor straight away if you notice any of the following &ndash; you may need urgent medical treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding into the brain or inside the skull is an uncommon side effect, and may cause signs of a stroke such as:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden numbness or weakness of your arm, leg or face, especially if only on one side of the body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion, difficulty speaking or understanding others</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden difficulty in walking or loss of balance or co-ordination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suddenly feeling dizzy or sudden severe headache with no known cause</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of bleeding such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding that is severe or that you cannot control</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexpected bleeding or bleeding that lasts a long time pink, red, or brown urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting red blood or your vomit looks like &lsquo;coffee grounds&rsquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red or black stools (look like tar)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up or vomiting blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting (syncope)</p><p>-&nbsp;&nbsp; a temporary loss of consciousness due to sudden drop in blood flow to the brain (common)</p><p>&bull;&nbsp; Signs of a blood clotting problem called Thrombotic Thrombocytopenic Purpura (TTP) such as:</p><p>-&nbsp; fever and purplish spots (called purpura) on the skin or in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained extreme tiredness or confusion</p><p>Discuss with your doctor if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeling short of breath - this is very common. </strong>It might be due to your heart disease or another cause, or it might be a side effect of Ticagrelor SPC. Ticagrelor SPC-related breathlessness is generally mild and characterized as a sudden, unexpected hunger for air usually occurring at rest and may appear in the first weeks of therapy and for many may disappear. If you&rsquo;re feeling of shortness of breath gets worse or lasts a long time, tell your doctor. Your doctor will decide if it needs treatment or further investigations.</p><p>Other possible side effects</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High level of uric acid in your blood (as seen in tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding caused by blood disorders</p><p>Common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or like the room is spinning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea or indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe pain and swelling in your joints &ndash; these are signs of gout</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or light-headed, or having blurred vision &ndash; these are signs of low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nosebleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding after surgery or from cuts (for example while shaving) and wounds more than is normal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from your stomach lining (ulcer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding gums</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction &ndash; a rash, itching, or a swollen face or swollen lips/tongue may be signs of an allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual problems caused by blood in your eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal bleeding that is heavier, or happens at different times, than your normal period (menstrual) bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding into your joints and muscles causing painful swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in your ear</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Internal bleeding, this may cause dizziness or light-headedness</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via submitting completed forms to: npc.drug@sfda.gov.sa . By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&ordm;C. Keep out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ticagrelor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: <u>Tablet Core:</u></p><p>Mannitol , Croscarmellose sodium, Hydroxypropyl cellulose, Purified water, Dicalcium phosphate Dihydrate, Magnesium stearate.</p><p><u>Tablet Coating:</u></p><p>Opadry yellow 03B520168</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Yellow, round, biconvex, film coated tablets, debossed with "M" on one side and "90" on other side.
Ticagrelor SPC 90 mg- Film Coated Tablets 
30 Count PVC/PVDC/Aluminium Blister Pack 
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Manufacturer</strong></p></td><td style="vertical-align:top"><p><strong>Marketing Authorization Holder</strong></p></td></tr><tr><td style="vertical-align:top"><p>MSN LABORATORIES PRIVATE</p><p>LIMITED, Formulations Division, Unit-II, Survey Nos. 1277 &amp; 1319 to 1324, Nandigama (Village &amp; Mandal), Rangareddy District, Telangana 509228, India</p></td><td style="vertical-align:top"><p>Sudair Pharma Company (SPC)</p><p>King Fahd Rd, Al Mohammadiyah Dist. Building No. 8006, P.O. Box 12363 Riyadh, 4432, 4th Floor, Office No. 32</p><p>Saudi Arabia</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي تيكاجريلور إس بي سي على المادة الفعّالة تيكاجريلور. ينتمي تيكاجريلور إلى مجموعة من الأدوية تُعرف بالأدوية المضادة لتجمع الصُّفَائح الدموية.</p><p>ما هي دواعي استعمال دواء تيكاجريلور إس بي سي؟</p><p dir="RTL">يتم استخدام تيكاجريلور إس بي سي بالتزامن مع حمض الأستيل ساليسيليك (عامل آخر مضاد لتجمع الصفائح الدموية) فقط في المرضى من البالغين. يتم وصف هذا الدواء لك، إذا كنت تعاني أيًا من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أزمة قلبية، أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذبحة صدرية غير مستقرة (ذبحة صدرية أو ألم بالصدر لا يمكن السيطرة عليه ومعالجته تمامًا).</p><p dir="RTL">يقلل هذا الدواء من معدل الإصابة بأزمة قلبية أخرى أو سكتة دماغية أو الأمراض المهددة للحياة المتعلقة بالقلب أو الأوعية الدموية.</p><p>كيفية عمل تيكاجريلور إس بي سي:</p><p dir="RTL">يؤثر تيكاجريلور إس بي سي على خلايا تُعرف باسم &quot;الصفائح الدموية&quot; (وتُعرف أيضًا بالصفيحات الدموية). تساعد خلايا الدم الصغيرة جدًا على وقف النزيف من خلال التكتل معًا لسد الثقوب الصغيرة الموجودة في الأوعية الدموية المتمزقة أو التالفة. وبالرغم من ذلك، قد تعمل الصفائح الدموية على تكوّين جلطات داخل الأوعية الدموية التالفة في القلب والمخ. قد يكون ذلك خطير جدًا للأسباب التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تؤدي الجلطات الدموية إلى إيقاف تدفق الدم تمامًا، مما يؤدي إلى الإصابة بأزمة قلبية (احتشاء عضلة القلب) أو سكتة دماغية، أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تؤدي الجلطات الدموية إلى إيقاف تدفق الدم جزئيًا في الأوعية الدموية بالقلب، مما يؤدي إلى انخفاض تدفق الدم إلى القلب ويُسبب ألم غير منتظم (غير مستمر) في الصدر (والذي &quot;يُعرف بذبحة صدرية غير مستقرة.&quot;)</p><p dir="RTL">يساعد تيكاجريلور إس بي سي على منع تكتل الصفائح الدموية. لذا يقلل من معدل تكوّين جلطات دموية التي تؤدي إلى انخفاض تدفق الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحظر تناول تيكاجريلور إس بي سي في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه تيكاجريلور أو تجاه أي مكون من المكونات الأخرى الداخلة في تركيب هذا الدَّواء (المدرجة في القسم رقم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من نزيف في الوقت الحالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من سكتة دماغية ناجمة عن الإصابة بنزيف في المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من أمراض خطيرة بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول (دواء يُستَخدَم لعلاج العدوى الفطرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كلاريثرومايسين (دواء يُستخدم لعلاج العدوى البكتيرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (دواء مضاد للاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير وأتازانافير (أدوية تُستَخدَم لعلاج عدوى فيروس نقص المناعة البشرية &quot;الإيدز&quot;).</p><p dir="RTL">يحظر تناول<strong> </strong>تيكاجريلور إس بي سي، إذا انطبق عليك أية حالة من الحالات السابقة. يُرجى استشارة الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول هذا الدواء، إذا لم تكن متأكدًا من كيفية التناول.</p><p>تحذيرات واحتياطات</p><p dir="RTL">استشر الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول<strong> </strong>تيكاجريلور إس بي سي في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من زيادة معدل التعرض للنزيف للأسباب التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مؤخرًا من إصابة خطيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت مؤخرًا لعملية جراحية (بما في ذلك جراحات الفم والأسنان، يرجى استشارة طبيب الأسنان الخاص بك حول هذا الأمر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة مرضية تؤثر على تجلط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مؤخرًا من نزيف المعدة أو الأمعاء (مثل قرحة المعدة أو القولون &quot;سلائل المعدة&quot;) (&quot;هي عبارة عن نتوء وتكتل للخلايا الداخلية على بطانة الداخلية للمعدة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط للخضوع لعملية جراحية (بما في ذلك جراحات الفم والأسنان) في أي وقت أثناء فترة تناول تيكاجريلور إس بي سي.</p><p dir="RTL">نظرًا إلى الخطورة المتزايدة للتعرض للنزيف. قد يطلب الطبيب المعالج لك إيقاف تناول هذا الدواء لمدة 5 أيام قبل الخضوع لعملية جراحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض معدل ضربات القلب بصورة غير طبيعية (عادة ما يكون أقل من 60 نبضة في الدقيقة) وليس لديك فعليًا جهاز لتنظيم ضربات القلب الخاصة بك (جهاز تنظيم ضربات القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الربو أو مشاكل أخرى بالرئة أو صعوبات في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أمراض بالكبد أوقد عانيت مُسبقًا من أي مرض يؤثر على الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا أجريت فحوصات الدم وأظهرت النتائج وجود كمية أكثر من المعتاد من حمض اليوريك.</p><p dir="RTL">إذا انطبق عليك أيِ من الحالات السابقة (أو إذا لم تكن متأكدًا)، فيُرجى التَّحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول هذا الدَّواء.</p><p dir="RTL">إذا كنت تتناول تيكاجريلور إس بي سي بالتزامن مع<strong> </strong>هيبارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب الطبيب المعالج لك الحصول على عينة من الدم لإجراء فحوصات تشخيصية في حالة الاشتباه بإصابتك باضطراب نادر بالصفائح الدموية ناتج عن استخدام هيبارين. يُعد مهمًا إبلاغ الطبيب المعالج لك أنك تتناول كلًا من تيكاجريلور إس بي سي بالتزامن مع هيبارين. حيث قد يؤثر تيكاجريلور إس بي سي على نتائج الفحوصات التشخيصية.</p><p>الاستخدام في المرضى من الأطفال والمراهقين</p><p>يحظر استخدام تيكاجريلور إس بي سي في المرضى من الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p>تناوُل تيكاجريلور بالتزامن مع الأدوية الأخرى</p><p dir="RTL">يُرجى إبلاغ الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. حيث قد يؤثر تيكاجريلور إس بي سي على طريقة عمل بعض الأدوية كما أن بعض الأدوية قد يكون لها تأثير على طريقة عمل تيكاجريلور إس بي سي.</p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أيّ من الأدوية التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة أكبر من 40 مجم يوميًا من سيمفاستاتين أو لوفاستاتين (أدوية تُستخدم لعلاج ارتفاع مستوى&nbsp;الكوليسترول في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (مضاد حيوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين كاربامازبين وفينوباربيتال (أدوية تُستخدم لعلاج نوبات الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (دواء يُستَخدَم لعلاج فشل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء يُستخدم لتثبيط المناعة حيث يقلل معدل رفض الجسم للأعضاء المزروعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين وديلتيازيم (أدوية تُستخدم لعلاج نظم القلب غير الطبيعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا وفيراباميل (أدوية تُستخدم لعلاج ضغط الدم المرتفع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مورفين والأدوية الأفيونية الأخرى (أدوية تُستخدم لعلاج الألم الشديد).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك، إذا كنت تتناول، على وجه الخصوص، أيًا من الأدوية التالية التي تزيد من معدل الإصابة بالنزيف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;مضادات التخثر التي يتم تناولها عن طريق الفم&quot; ويشار إليها غالبًا باسم &quot;أدوية زيادة سيولة الدم أو مضادات تخثر الدم&quot; التي تشتمل على وارفارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب عير الستيرويدية (ويُرمز إليها باختصار (NSAIDs حيث يتم استخدامها كمسكنات للألم مثل إيبوبروفين ونابروكسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات استرداد السيروتونين الانتقائية (ويُرمز إليها باختصار SSRIs) التي يتم استخدامها كمضادات للاكتئاب مثل، باروكستين وسيرترالين وسيتالوبرام.<em> </em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى مثل: كيتوكونازول (دواء يُستخدم لعلاج العدوى الفطرية)، كلاريثرومايسين (مضاد حيوي يُستخدم لعلاج العدوى البكتيرية)، نيفازودون (دواء مضاد للاكتئاب)، ريتونافير وأتازانافير (أدوية تُستَخدَم لعلاج عدوى فيروس نقص المناعة البشرية المكتسب والإيدز)، سيسابريد (دواء يُستخدم لعلاج حموضة المعدة)، قلويدات الأرغوت (تُستخدم لعلاج الصداع النصفي والكلي).</p><p dir="RTL">كما يُرجى أيضًا إبلاغ الطبيب المعالج لك أنك تناول تيكاجريلور إس بي سي، حيث قد يؤدي تناول تيكاجريلور إلى زيادة معدل التعرض للنزيف إذا تم إعطائك مواد حّالة للفبرين، التي تُعرف غالبًا &quot;بمذيبات التخثر&quot; مثل ستربتوكيناز أو منشط البلازمينوجين النسيجي &quot;ألتيبلاز&quot;.</p><p>الحمل والرضاعة الطبيعية:</p><p dir="RTL">يحظر تناول تيكاجريلور إس بي سي، إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا. يُوصى المرضى من السيدات باستخدام وسائل فعّالة لمنع الحمل أثناء فترة تناول هذا الدواء.</p><p dir="RTL">إذا كنتِ تمارسين الرضاعة الطبيعية، يُرجى استشارة الطبيب المعالج لكِ قبل تناوُل هذا الدَّواء.<br />سيقوم الطبيب المعالج لكِ بمناقشة الفوائد المرجوة والمخاطر المُحتملة الناجمة عن تناوُل تيكاجريلور إس بي سي أثناء ممارسة الرضاعة الطبيعية.</p><p dir="RTL">يُرجى استشارة الطبيب المعالج لك أو الصيدلي الخاص بكِ، إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، للحصول على النصيحة قبل استخدام هذا الدَّواء.</p><p>قيادة السيارات واستخدام الآلات:</p><p dir="RTL">من غير المحتمل أن يُؤثر تيكاجريلور إس بي سي على القدرة على قيادة السيارات أو استخدام الآلات، يُرجى توخي الحذر عند قيادة السيارات أو استخدام الآلات، إذا شعرت بدوخة أو ارتباك أثناء فترة تناول هذا الدواء.</p><p>نسبة الصوديوم الداخلة في تركيب هذا الدواء</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل جرعة، مما يعني أنه &quot;شبه خالي بشكل أساسي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدَّواء دائمًا كما أخبرك الطبيب المعالج لك تمامًا. استشر الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناول.</p><p>مقدار الجرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء هي قرصين في نفس الوقت (جرعة البدء القصوى &quot;جرعة بدء عالية &lrm;&quot; وهي 180 مجم). عادة ما يتم إعطائك هذه الجرعة في المستشفى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المُوصى بها، بعد جرعة البدء، هي قرص واحد 90 مجم مرتين يوميًا لمدة تصل إلى 12 شهرًا مالم يُخبرك الطبيب المعالج لك بخلاف ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;استمر في تناول هذا الدواء في نفس الوقت يوميًا (على سبيل المثال، قرص واحد صباحًا وقرص آخر مساءً).</p><p>تناول تيكاجريلور إس بي سي بالتزامن مع غيره من الأدوية لعلاج تجلط الدم.</p><p dir="RTL">بالإضافة إلى ذلك، سيتم إخبارك عادةً بتناوُل حمض الأسيتيل ساليسيليك. حيث تدخل هذه المادة في العديد من الأدوية التي تُستخدم لمنع تجلط الدم. سيخبرك الطبيب المعالج لك بمقدار الجرعة التي يجب تناولها (تتراوح عادةً ما بين 75- 150 مجم يوميًا).</p><p>كيفية تناول تيكاجريلور إس بي سي&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن تناوُل الأقراص مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك معرفة آخر مرة تناولت فيها قرصًا من تيكاجريلور إس بي سي من خلال النظر إلى شريط الدواء. ستلاحظ وجود رمز شمس (يُشير إلى جرعة التي يجب تناولها صباحًا) ورمز قمر (يُشير إلى الجرعة التي يجب تناولها مساءً). سيُساعدك هذا على معرفة الجرعة المحددة التي يجب عليك تناولها.</p><p>إذا واجهت صعوبة في ابتلاع الأقراص:</p><p dir="RTL">&nbsp;إذا واجهت صعوبة في ابتلاع القرص، يمكنك طحنه وخلطه بالماء على النحو التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اطحن القرص حتى يتحوّل إلى مسحوق ناعم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اخلط المسحوق مع نصف كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تقليب المسحوق ويُشَرّب على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتأكد من عدم وجود دواء متبقي، املأ الكوب الفارغ بمقدار نصف كوب آخر من الماء واشربه.</p><p dir="RTL">إذا كنت في المستشفى، فقد يتم إعطاؤك هذا القرص ممزوجًا ببعض الماء من خلال أنبوب عبر الأنف يصل إلى المعدة (أنبوب أنفي معدي).</p><p>إذا تناولت كمية أكثر مما يجب من تيكاجريلور إس بي سي:</p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من تيكاجريلور إس بي سي، فتحدَّث إلى الطبيب المعالج لك أو توجه إلى أقرب مستشفى على الفور. وقم بأخذ عبوة الدواء معك، فقد تكون أكثر عرضةً لخطر الإصابة بنزيف.</p><p>إذا نسيتِ تناول تيكاجريلور إس بي سي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناوُل جرعة من تيكاجريلور، فتناول الجرعة التَّالية كالمعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة (جرعتين في نفس الوقت) لتعويض الجرعة التي نسيتها.</p><p>إذا توقفت عن تناول تيكاجريلور إس بي سي</p><p dir="RTL">لا تتوقف عن تناول تيكاجريلور إس بي سي دون استشارة إلى الطبيب المعالج لك. استمر في تناوُل هذا الدواء بانتظام مالم يخبرك الطبيب المعالج لك بخلاف ذلك. إذا توقفت عن تناول تيكاجريلور إس بي سي، فقد يزيد ذلك من فرص الإصابة بنوبة قلبية أخرى أو سكتة دماغية أو قد يتسبب في الوفاة نتيجة الإصابة بمرض مرتبط بالقلب أو الأوعية الدموية.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدَّواء، مثله مثل كافة الأدوية، آثارًا جانبية، على الرغم من عدم حدوثها لجميع المرضى. قد تَحدُث الآثار الجانبية التَّالية مع هذا الدَّواء:</p><p dir="RTL">يؤثر تيكاجريلور إس بي سي على تجلط الدم، لذلك ترتبط معظم الآثار الجانبية بالإصابة بنزيف. قد تتعرض للإصابة بنزيف في أي جزء من أجزاء الجسم.</p><p dir="RTL">بعض حالات النزيف الشائعة (مثل كدمات ونزيف الأنف &quot;رُعاف&quot;). نزيف حاد غير شائع ولكن يمكن أن يكون مهددًا للحياة.</p><p>استشر الطبيب المعالج لك فورًا إذا لاحظت أيًا من الآثار الجانبية التالية، فقد تحتاج إلى رعاية طبية عاجلة</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نزيف بالدماغ أو داخل الجمجمة وهو أحد الآثار الجانبية غير الشائعة، وقد يسبب أعراض السكتة الدماغية مثل ما يلي</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; خدر أو ضعف مفاجئ في الذراع أو الرجل أو الوجه، وبشكل خاص إذا كان ذلك في جانب واحد فقط من الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ارتباك مفاجئ أو صعوبة في التحدث أو فهم الآخرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; صعوبة مفاجئة عند المشي أو فقدان التوازن والتناسق أثناء الحركة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; دوار مفاجئ أو صداع حاد مفاجئ دون سبب معروف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات تُشير إلى حدوث نزيف، مثل ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; نزيف شديد أو نزيف لا يمكن إيقافه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير متوقع أو نزيف مستمر لفترة طويلة يتسبب بتغيير لون البول إلى اللون الوردي أو الأحمر أو البني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قيء مصحوب بدم أو قيء يبدو مثل &quot;ثفل القهوة&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تغيير لون البراز إلى اللون الأحمر أو الأسود (يبدو مثل القطران).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; سعال أو قيء مصحوبًا بجلطات دموية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِغْماء (فقدان الوعي)</p><p dir="RTL">- فقدان مؤقت للوعي بسبب الانخفاض المفاجئ في تدفق الدم إلى الدماغ (آثر جانبي شائع).</p><p>&bull; علامات تُشير إلى مشاكل متعلقة بتجلط الدم تسمى فُرْفُرِيَّةُ نَقْصِ الصَّفِيحاتِ التَخَثُّرِيَّة (TTP) مثل:</p><p>- حمى وبقع أرجوانية (تسمى فرفرية) تظهر على الجلد أو في الفم، مع أو بدون اصفرار الجلد أو العينين (يرقان)، تعب شديد مجهول السبب أو ارتباك.</p><p>استشر الطبيب المعالج لك إذا لاحظت أيًّا من الآثار الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بضيق في التنفس (آثر جانبي شائع جدًا).<strong> </strong>قد يكون بسبب مرض في القلب أو لأي سبب آخر، أو قد يكون أحد الآثار الجانبية الناجمة عن تيكاجريلور إس بي سي. يكون ضيق التنفس الناجم عن تيكاجريلور إس بي سي خفيفًا بشكل عام ومفاجئ وصعوبة في التنفس تحدث عادةً أثناء الراحة وقد يظهر في الأسابيع الأولى من تلقّي العلاج وقد يزول عادة من تلقاء نفسه عند الكثير من المرضى. أخبر الطبيب المعالج لك، إذا كنت تشعر بأن ضيق التنفس يزداد سوءًا أو يستمر لفترة طويلة. سيقرر الطبيب المعالج لكِ ما إذا كانت الحالة تتطلّب علاجًا أو اجراء المزيد من الفحوصات.</p><p>الآثار الجانبية المحتملة الأخرى</p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا </strong><strong>(</strong><strong>تُؤثر على أكثر من مريض واحد من بين كل </strong><strong>10 </strong><strong>مرضى</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى حَمْض اليوريك في الدَّم (كما يظهر في اختبارات الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف ناجم عن اضطرابات الدَّم.</p><p>آثار جانبية شائعة: (تؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بدوار أو الشعور بدوران الغرفة من حولك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو عسر الهضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بإعياء (غثيان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد وتورم في المفاصل &ndash; يُعد علامة على الإصابة بمرض النقرس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بدوخة أو عدم وضوح الرؤية، تُعدّ علامات على انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بعد الجراحة أو نزيف نتيجة للإصابة بجروح (على سبيل المثال أثناء الحلاقة) والتعرّض لجروح أكثر من المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بطانة المعدة (قرحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف اللثة.</p><p>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية مثل طفح جلدي أو حكة أو تورم الوجه أو الشفتين/اللسان قد يعد ذلك علامات تشير إلى تفاعلات حساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث مشاكل بالرؤية بسبب تواجد دماء داخل العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف مهبلي غزير أكثر من نزيف الدورة الشهرية وفي أوقات مختلفة عن نزيف (الحيض)&lrm;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخلي في المفاصل والعضلات يسبب تورم مؤلم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;وجود دم في الأذن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخلي قد يسبب دوار أو دوخة.</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا عانيت من أية آثار جانبية، فتحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة غير مُدرجة في هذه النَّشرة. <u>كما يمكنك الإبلاغ عن الآثار الجانبية بشكل مباشر عن طريق ملء وتقديم النماذج الكاملة وإرسالها إلى البريد الإلكتروني التالي: </u><u>npc.drug@sfda.gov.sa، </u>يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان استخدام هذا الدَّواء من خلال إبلاغك عن الآثار الجانبية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحظر حفظ الدواء في درجة حرارة تتجاوز 30&ordm; درجة مئوية. يُحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تتناول هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الشريط والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف الصحي أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;)&nbsp;&nbsp;&nbsp; محتويات تيكاجريلور إس بي سي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي تيكاجريلور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشتمل المكونات الأخرى (المواد غير الفعالة) لهذا الدواء على ما يلي:</p><p dir="RTL"><strong><u>مكونات المحتوى الداخلي للقرص:</u></strong></p><p dir="RTL">مانيتول، كروس كارميلوز الصوديوم، هيدروكسي بروبيل السليلوز، ماء مُنقي، فوسفات ثنائي الكالسيوم ثنائي الهيدرات، ستيرات الماغنيسيوم.</p><p dir="RTL"><strong><u>مكونات الغلاف الخارجي للقرص:</u></strong></p><p dir="RTL">أوبادري أصفر B520168 03</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مغلفة دائرية الشكل ثنائية التحدب، لونها أصفر، محفور على أحد جانبيها &quot;M&quot; وعلى الجانب الآخر &quot;90&quot;.</p><p>تيكاجريلور إس بي سي 90 مجم أقراص مغلَّفة</p><p dir="RTL"><u>30 قرص معبأ في شرائط مصنوعة من الألمنيوم/ كلوريد متعدد الفاينيل /كلوريد الفينيليدين،<br />&nbsp;قد لا يتم تسويق جميع أحجام العبوات.</u></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;الشركة المُصنعة </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الشركة صاحبة حق التَّسويق</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">مختبرات إم إس إن الخاصة المحدودة، قسم التركيبات الصيدلانية، وحدة رقم-2، إحصاءات رقم 1277، 1319 حتى 1324،</p><p dir="RTL">نانديجاما، (فاليج/ماندال)، حي رانجاريدي، تيلانجانا 509228، الهند.</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، حي المحمدية. مبنى رقم 8006، صندوق بريدي 12363 الرياض 4432 الدور الرابع مكتب 32.</p><p dir="RTL">&bull;المملكة العربية السعودية</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ticagrelor SPC Tablets 60 mg 
Ticagrelor SPC Tablets 90 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ticagrelor SPC Tablets 60 mg
Each film-coated tablet contains Ticagrelor 60mg Ticagrelor SPC Tablets 90 mg
Each film-coated tablet contains Ticagrelor 90 mg Ticagrelor SPC contains less than 1 mmol sodium (23mg) per dose , i.e is essentially “Sodium-Free”For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor SPC Tablets, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with</p><p>- acute coronary syndromes (ACS) or</p><p>a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Patients taking Ticagrelor SPC Tablets should also take a daily low maintenance dose of ASA 75- 150 mg, unless specifically contraindicated.</p><p><em><u>Acute coronary syndromes</u></em></p><p>Ticagrelor SPC Tablets treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.</p><p>Treatment with Ticagrelor SPC Tablets 90 mg twice daily is recommended for 12 months in ACS patients unless discontinuation is clinically indicated (see section 5.1).</p><p><em><u>History of myocardial infarction</u></em></p><p>Ticagrelor Tablets 60 mg twice daily is the recommended dose when an extended treatment is required for patients with a history of MI of at least one year and a high risk of an atherothrombotic event (see section 5.1) . Treatment may be started without interruption as continuation therapy after the initial one-year treatment with Ticagrelor SPC 90 mg or other adenosine diphosphate (ADP) receptor inhibitor therapy in ACS patients with high risk of an atherothrombotic event. Treatment can also be initiated up to 2 years from MI, or within one year after stopping previous ADP receptor inhibitor treatment. There are limited data on the efficacy and safety of Ticagrelor beyond 3 years extended treatment.If a switch is needed, the first dose of Ticagrelor SPC should be administered 24 hours following the last dose of the other antiplatelet medication.</p><p>For patients who are unable to swallow the tablet(s) whole, the tablets can be crushed to a fine powder and mixed in half a glass of water and drunk immediately. The glass should be rinsed with a</p><p><em><u>Missed dose</u></em></p><p>Lapses in therapy should also be avoided. A patient who misses a dose of Ticagrelor SPC Tablets should take only one tablet (their next dose) at its scheduled time.</p><p><strong><u>Special populations</u></strong></p><p><em>Elderly</em></p><p>No dose adjustment is required in elderly (see section 5.2).</p><p><strong><em>Renal impairment</em></strong></p><p>No dose adjustment is necessary for patients with renal impairment (see section 5.2).</p><p>No information is available concerning treatment of patients on renal dialysis and therefore ticagrelor is not recommended in these patients.</p><p><strong><em>Hepatic impairment</em></strong></p><p>Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated (see section 4.3). Only limited information is available in patients with moderate hepatic impairment. Dose adjustment is not recommended, but ticagrelor should be used with caution (see sections 4.4 and 5.2). No dose adjustment is necessary for patients with mild hepatic impairment (see section 5.2).</p><p><strong><em>Paediatric population</em></strong></p><p>The safety and efficacy of ticagrelor in children below the age of 18 years have not been established. No data are available.</p><p><u>Method of administration</u> For oral use.</p><p>Ticagrelor SPC Tablets can be administered with or without food.</p><p>For patients who are unable to swallow tablet(s) whole, the tablets can be crushed to a fine powder and mixed in half a glass of water and drunk immediately. The glass should be rinsed with a further half glass of water and the contents drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater). It is important to flush the nasogastric tube through with water after administration of the mixture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (seesection 4.8).
•	Active pathological bleeding.
•	History of intracranial haemorrhage (see section 4.8).
•	Severe hepatic impairment (see section 4.2, 4.4 and 5.2).
•	Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir), as co-administration may lead to a substantial increase in exposure to ticagrelor (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bleeding risk</u></p><p>The use of ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events (see sections 4.8 and 5.1). If clinically indicated, ticagrelor should be used with caution in the following patient groups:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding). The use of ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial haemorrhage, and in patients with severe hepatic impairment (see section 4.3).</p><p>&bull;&nbsp;&nbsp;&nbsp; Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of ticagrelor dosing.</p><p>Platelet transfusion did not reverse the antiplatelet effect of ticagrelor in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding. Since co-administration of ticagrelor with desmopressin did not decrease template-bleeding time, desmopressin is unlikely to be effective in managing clinical bleeding events (see section 4.5).</p><p>Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor VIIa</p><p>therapy may increase haemostasis. Ticagrelor may be resumed after the cause of bleeding has been identified and controlled.</p><p><u>Surgery</u></p><p>Patients should be advised to inform physicians and dentists that they are taking ticagrelor before any surgery is scheduled and before any new medicinal product is taken.</p><p>In PLATO patients undergoing coronary artery bypass grafting (CABG), ticagrelor had more bleeding than clopidogrel when stopped within 1 day prior to surgery but a similar rate of major bleeds compared to clopidogrel after stopping therapy 2 or more days before surgery (see section 4.8). If a patient is to undergo elective surgery and antiplatelet effect is not desired, ticagrelor should be discontinued 5 days prior to surgery (see section 5.1).</p><p><u>Patients with prior ischaemic stroke</u></p><p>ACS patients with prior ischaemic stroke can be treated with ticagrelor for up to 12 months (PLATO study).</p><p>In PEGASUS, patients with history of MI with prior ischaemic stroke were not included. Therefore, in the absence of data, treatment beyond one year is not recommended in these patients.</p><p><u>Hepatic impairment</u></p><p>Use of ticagrelor is contraindicated in patients with severe hepatic impairment (see sections 4.2 and 4.3). There is limited experience with ticagrelor in patients with moderate hepatic impairment, therefore, caution is advised in these patients (see sections 4.2 and 5.2).</p><p><u>Patients at risk for bradycardic events</u></p><p>Holter ECG monitoring has shown an increased frequency of mostly asymptomatic ventricular pauses during treatment with ticagrelor compared with clopidogrel. Patients with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope) have been excluded from the main studies evaluating the safety and efficacy of ticagrelor. Therefore, due to the limited clinical experience, ticagrelor should be used with caution in these patients (see section 5.1).</p><p>In addition, caution should be exercised when administering ticagrelor concomitantly with medicinal products known to induce bradycardia. However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin) (see section 4.5).</p><p>During the Holter substudy in PLATO, more patients had ventricular pauses <u>&gt;</u>3 seconds with ticagrelor than with clopidogrel during the acute phase of their ACS. The increase in Holter-detected ventricular pauses with ticagrelor was higher in patients with chronic heart failure (CHF) than in</p><p>overall study population during the acute phase of ACS, but not at one month with ticagrelor or compared to clopidogrel. There were no adverse clinical consequences associated with this imbalance (including syncope or pacemaker insertion) in this patient population (see section 5.1).</p><p><u>Dyspnoea</u></p><p>Dyspnoea was reported in patients treated with ticagrelor. Dyspnoea is usually mild to moderate in intensity and often resolves without need for treatment discontinuation. Patients with asthma/chronic obstructive pulmonary disease (COPD) may have an increased absolute risk of experiencing dyspnoea with ticagrelor. Ticagrelor should be used with caution in patients with history of asthma and/or COPD. The mechanism has not been elucidated. If a patient reports new, prolonged or worsened dyspnoea this should be investigated fully and if not tolerated, treatment with ticagrelor should be stopped. For further details see section 4.8.</p><p><u>Creatinine elevations</u></p><p>Creatinine levels may increase during treatment with ticagrelor. The mechanism has not been elucidated. Renal function should be checked according to routine medical practice. In patients with ACS, it is recommended that renal function is also checked one month after initiating the treatment with ticagrelor, paying special attention to patients &ge; 75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an angiotensin receptor blocker (ARB). <u>Uric acid increase</u></p><p>Hyperuricaemia may occur during treatment with ticagrelor (see section 4.8). Caution is advised in patients with history of hyperuricaemia or gouty arthritis. As a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged.</p><p><u>Thrombotic Thrombocytopenic Purpura (TTP)</u></p><p>Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely with the use of ticagrelor. It is characterised</p><p>by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal</p><p>dysfunction or fever. TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.</p><p>Interference with platelet function tests to diagnose heparin induced thrombocytopenia (HIT)</p><p>In the heparin induced platelet activation (HIPA) test used to diagnose HIT, anti-platelet factor 4/heparin antibodies in</p><p>patient serum activate platelets of healthy donors in the presence of heparin.</p><p>False negative results in a platelet function test (to include, but may not be limited to the HIPA test) for HIT have been</p><p>reported in patients administered ticagrelor. This is related to inhibition of the P2Y12-receptor on the healthy donor platelets in the test by ticagrelor in the patient&rsquo;s sera/plasma. Information on concomitant treatment with ticagrelor is required for interpretation of HIT platelet functiontest.</p><p>In patients who have developed HIT, the benefit-risk of continued treatment with ticagrelor should be assessed, taking both the prothrombotic state of HIT and the increased risk of bleeding with concomitant anticoagulant and ticagrelor treatment into consideration.</p><p><u>Other</u></p><p>Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacyof ticagrelor compared to clopidogrel, co-administration of ticagrelor and high maintenance dose ASA (&gt;300 mg) is not recommended (see section 5.1).</p><p><u>Premature discontinuation</u></p><p>Premature discontinuation with any antiplatelet therapy, including Ticagrelor SPC Tablets, could result in an increased risk of cardiovascular (CV) death, MI or stroke due to the patient&#39;s underlying disease. Therefore, premature discontinuation of treatment should be avoided</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P- glycoprotein (P-gp) substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates.</p><p><u>Effects of medicinal and other products on ticagrelor</u></p><p><em><u>CYP3A4 inhibitors</u></em></p><p>&bull;&nbsp;&nbsp;&nbsp; Strong CYP3A4 inhibitors &ndash; Co-administration of ketoconazole with ticagrelor increased the ticagrelor Cmax and AUC equal to 2.4-fold and 7.3-fold, respectively. The Cmax and AUC of the active metabolite were reduced by 89% and 56%, respectively. Other strong inhibitors of CYP3A4 (clarithromycin, nefazodone, ritonavir, and atazanavir) would be expected to have similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is contraindicated (see section 4.3).</p><p>&bull;&nbsp;&nbsp;&nbsp; Moderate CYP3A4 inhibitors &ndash; Co-administration of diltiazem with ticagrelor increased the ticagrelor Cmax by 69% and AUC to 2.7-fold and decreased the active metabolite Cmax by 38% and AUC was unchanged. There was no effect of ticagrelor on diltiazem plasma levels. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole) would be expected to have a similar effect and can as well be co-administered withticagrelor.</p><p>&bull;&nbsp; A 2-fold increase of ticagrelor exposure was observed after daily consumption of large quantities of grapefruit juice (3x 200 ml). This magnitude of increased exposure is not expected to be clinically relevant to most patients.</p><p><em><u>CYP3A inducers</u></em></p><p>Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86%, respectively. The Cmax of the active metabolite was unchanged and the AUC was decreased by 46%, respectively. Other CYP3A inducers (e.g. phenytoin, carbamazepine and phenobarbital) would be expected to decrease the exposure to ticagrelor as well. Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor, therefore, their concomitant use with ticagrelor is discouraged.</p><p><em><u>Cyclosporine (P-gp and CYP3A inhibitor)</u></em></p><p>Co-administration of cyclosporine (600 mg) with ticagrelor increased ticagrelor Cmax and AUC equal to 2.3-fold and 2.8-fold, respectively. The AUC of the active metabolite was increased by 32% and Cmax was decreased by 15% in the presence of cyclosporine.</p><p>No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp inhibitors and moderate CYP3A4 inhibitors (e.g. verapamil, quinidine) that also may increase ticagrelor exposure. If the association cannot be avoided, their concomitant use should be made with caution.</p><p><em><u>Others</u></em></p><p>Clinical pharmacology interaction studies showed that co-administration of ticagrelor with heparin, enoxaparin and ASA or desmopressin did not have any effect on the pharmacokinetics of ticagrelor or the active metabolite or on ADP-induced platelet aggregation compared with ticagrelor alone. If clinically indicated, medicinal products that alter haemostasis should be used with caution in combination with ticagrelor.</p><p>A delayed and decreased exposure to oral P2Y12 inhibitors, including ticagrelor and its active metabolite, has been observed in patients with ACS treated with morphine (35% reduction in ticagrelor exposure). This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced ticagrelor efficacy in patients co-administered ticagrelor and morphine. In patients with ACS, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may beconsidered.</p><p><u>Effects of ticagrelor on other medicinal products</u></p><p><em><u>Medicinal products metabolised by CYP3A4</u></em></p><p>&bull;&nbsp; <em>Simvastatin </em>&ndash; Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3-fold. Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse reactions of simvastatin and should be weighed against potential benefits. There was no effect of simvastatin on ticagrelor plasma levels. Ticagrelor may have similar effect on lovastatin. The concomitant use of ticagrelor with doses of simvastatin or lovastatin greater than 40 mg is not recommended.</p><p>&bull;&nbsp; <em>Atorvastatin </em>- Co-administration of atorvastatin and ticagrelor increased atorvastatin acid Cmax by 23% and AUC by 36%. Similar increases in AUC and Cmax were observed for all atorvastatin acid metabolites. These increases are not considered clinically significant.</p><p>&bull;&nbsp; A similar effect on other statins metabolised by CYP3A4 cannot be excluded. Patients in PLATO receiving ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% of the PLATO cohort taking these medicinal products.</p><p>Ticagrelor is a mild CYP3A4 inhibitor. Co-administration of ticagrelor and CYP3A4 substrates with narrow therapeutic indices (i.e. cisapride or ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products.</p><p><em><u>P-gp substrates (including digoxin, cyclosporine)</u></em></p><p>Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%. The mean trough digoxin levels were increased about 30% with ticagrelor co-administration with some individual maximum increases to 2 fold. In the presence of digoxin, the Cmax and AUC of ticagrelor and its active metabolite were not affected. Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digoxin concomitantly with ticagrelor.</p><p>There was no effect of ticagrelor on cyclosporine blood levels. Effect of ticagrelor on other P-gp substrates has not been studied.</p><p><em><u>Medicinal products metabolised by CYP2C9</u></em></p><p>Co-administration of ticagrelor with tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggests that ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like warfarin and tolbutamide.</p><p><em><u>Oral contraceptives</u></em></p><p>Co-administration of ticagrelor and levonorgestrel and ethinyl estradiol increased ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of levonorgestrel. No clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are co-administered with ticagrelor.</p><p><em><u>Medicinal products known to induce bradycardia</u></em></p><p>Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering ticagrelor concomitantly with medicinal products known to induce bradycardia (see section 4.4). However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin).</p><p><em><u>Other concomitant therapy</u></em></p><p>In clinical studies, ticagrelor was commonly administered with ASA, proton pump inhibitors, statins, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers as needed for concomitant conditions for long-term and also heparin, low molecular weight heparin and intravenous GpIIb/IIIa inhibitors for short durations (see section 5.1). No evidence of clinically significant adverse interactions with these medicinal products was observed.</p><p>Co-administration of ticagrelor with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays. However, due to potential pharmacodynamic interactions, caution should be exercised with the concomitant administration of ticagrelor with medicinal products known to alter haemostasis.</p><p>Due to reports of cutaneous bleeding abnormalities with SSRIs (e.g. paroxetine, sertraline and citalopram), caution is advised when administering SSRIs with ticagrelor as this may increase the risk of bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during ticagrelor therapy.</p><p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of ticagrelor in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Ticagrelor is not recommended during pregnancy.</p><p><u>Breast-feeding</u></p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of ticagrelor and its active metabolites in milk (see section 5.3). A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. <u>Fertility</u></p><p>Ticagrelor had no effect on male or female fertility in animals (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor has no or negligible influence on the ability to drive and use machines. During treatment with ticagrelor, dizziness and confusion have been reported. Therefore, patients who experience these symptoms should be cautious while driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of ticagrelor has been evaluated in two large phase 3 outcome trials (PLATO and PEGASUS) including more than 39,000 patients (see section 5.1).</p><p>In PLATO, patients on ticagrelor had a higher incidence of discontinuation due to adverse events than clopidogrel (7.4% vs. 5.4%). In PEGASUS, patients on ticagrelor had a higher incidence of discontinuation due to adverse events compared to ASA therapy alone (16.1% for ticagrelor 60 mg with ASA vs. 8.5% for ASA therapy alone). The most commonly reported adverse reactions in patients treated with ticagrelor were bleeding and dyspnoea (see section 4.4).</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been identified following studies or have been reported in post- marketing experience with ticagrelor (Table 1).</p><p>Adverse reactions are listed by MedDRA and System Organ Class (SOC). Within each SOC the adverse reactions are ranked by frequency category. Frequency categories are defined according to the following conventions: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Table 1 Adverse reactions by frequency and system organ class (SOC)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>SOC</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Neoplasms benign, malignant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and unspecified&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (including</em></p><p><em>cysts and polyps)</em></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tumour bleedings<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Blood</em><em>&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lymphatic</em></p><p><em>system disorders</em></p></td><td style="vertical-align:top"><p>Blood</p><p>bleedings<sup>b</sup></p></td><td style="vertical-align:top"><p>disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombotic Thrombocytopenic Purpura<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Immune</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p><em>system</em></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>including angioedemac</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism</em></p></td><td style="vertical-align:top"><p><em>and</em></p></td><td colspan="2" style="vertical-align:top"><p>Hyperuricaemia<sup>d</sup></p></td><td style="vertical-align:top"><p>Gout/Gouty Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>nutrition disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Confusion</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p><em>system</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness,</p><p>Headache</p></td><td style="vertical-align:top"><p>Syncope,</p></td><td colspan="2" style="vertical-align:top"><p>Intracranial</p><p>haemorrhage</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Eye haemorrhage<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Ear</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p><em>labyrinth</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Vertigo</p></td><td colspan="2" style="vertical-align:top"><p>Ear haemorrhag<sup>e</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Hypotension</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Respiratory,</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoracic</em></p><p><em>and</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Respiratory bleedings<sup>f</sup></p></td><td style="vertical-align:top"><p>system</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal haemorrhage<sup>g</sup>, Diarrhoea,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, Dyspepsia,</p><p>Constipation</p></td><td colspan="2" style="vertical-align:top"><p>Retroperitoneal haemorrhage</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Subcutaneous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or dermal bleeding<sup>h</sup>, Rash,</p><p>Pruritus</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal</em></p><p><em>connective tissue and bone</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Muscular bleedings<sup>i</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Renal</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p><em>urinary</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Urinary tract bleeding<sup>j</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Reproductive</em><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system</em></p><p><em>and breast disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Reproductive</p><p>bleedings<sup>k</sup></p></td><td style="vertical-align:top"><p>system</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood</p><p>increased<sup>d</sup></p></td><td style="vertical-align:top"><p>creatinine</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Injury, poisoning and</em></p><p><em>procedural complications</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Post&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; procedural</p><p>haemorrhag<sup>e</sup>, Traumatic bleedings<sup>l</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> e.g. bleeding from bladder cancer, gastric cancer, colon cancer</p><p><sup>b</sup> e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis</p><p><sup>c</sup> Identified in post-marketing experience</p><p><sup>d</sup> Frequencies derived from lab observations (Uric acid increases to &gt;upper limit of normal from baseline below or within reference range. Creatinine increases of &gt;50% from baseline.) and not crude adverse event report frequency.</p><p><sup>e</sup> e.g. conjunctival, retinal, intraocular bleeding</p><p><sup>f</sup> e.g. epistaxis, haemoptysis</p><p><sup>g</sup> e.g. gingival bleeding, rectal haemorrhage, gastric ulcer haemorrhage</p><p><sup>h</sup> e.g. ecchymosis, skin haemorrhage, petechiae</p><p><sup>i</sup> e.g. haemarthrosis, muscle haemorrhage</p><p><sup>j</sup> e.g. haematuria, cystitis haemorrhagic</p><p><sup>k</sup> e.g. vaginal haemorrhage, haematospermia, postmenopausal haemorrhage</p><p><sup>l</sup> e.g. contusion, traumatic haematoma, traumatic haemorrhage</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Bleeding</u></em></p><p><em>Bleeding findings in PLATO</em></p><p>Overall outcome of bleeding rates in the PLATO study are shown in Table 2.</p><p>Table 2 &ndash;Analysis of overall bleeding events, Kaplan-Meier estimates at 12 months (PLATO)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ticagrelor 90 mg twice daily</strong></p><p><strong>N=9235</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel</strong></p><p><strong>N=9186</strong></p></td><td style="vertical-align:top"><p><strong><em>p-</em></strong><strong>value*</strong></p></td></tr><tr><td style="vertical-align:top"><p>PLATO Total Major</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.4336</p></td></tr><tr><td style="vertical-align:top"><p>PLATO Major Fatal/Life-Threatening</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>0.6988</p></td></tr><tr><td style="vertical-align:top"><p>Non-CABG PLATO Major</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>0.0264</p></td></tr><tr><td style="vertical-align:top"><p>Non-Procedural PLATO Major</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>0.0058</p></td></tr><tr><td style="vertical-align:top"><p>PLATO Total Major + Minor</p></td><td style="vertical-align:top"><p>16.1</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>0.0084</p></td></tr><tr><td style="vertical-align:top"><p>Non-Procedural PLATO Major + Minor</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>TIMI-defined Major</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>0.5669</p></td></tr><tr><td style="vertical-align:top"><p>TIMI-defined Major + Minor</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>0.3272</p></td></tr></tbody></table><p><strong>Bleeding category definitions:</strong></p><p><strong>Major Fatal/Life-threatening Bleed: </strong>Clinically apparent with &gt;50 g/L decrease in haemoglobin or</p><p>&ge;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red&nbsp;&nbsp;&nbsp;&nbsp; cell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; units&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transfused; <u>or</u> fatal; <u>or</u> intracranial; <u>or</u> intrapericardial&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac tamponade; <u>or</u> with hypovolaemic shock or severe hypotension requiring pressors or surgery.</p><p><strong>Major Other: </strong>Clinically apparent with 30-50 g/L decrease in haemoglobin or 2-3 red cell units transfused; <u>or</u> significantly disabling.</p><p><strong>Minor Bleed: </strong>Requires medical intervention to stop or treat bleeding.</p><p><strong>TIMI Major Bleed: </strong>Clinically apparent with &gt;50 g/L decrease in haemoglobin <u>or</u> intracranial haemorrhage.</p><p><strong>TIMI Minor Bleed: </strong>Clinically apparent with 30-50 g/L decrease in haemoglobin.</p><p>*<em>p</em>-value calculated from Cox proportional hazards model with treatment group as the only explanatory variable.</p><p>Ticagrelor and clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2). However, more PLATO combined Major + Minor bleeding occurred with ticagrelor compared with clopidogrel. Few patients in PLATO had fatal bleeds: 20 (0.2%) for ticagrelor and 23 (0.3%) for clopidogrel (see section 4.4).</p><p>Age, sex, weight, race, geographic region, concurrent conditions, concomitant therapy, and medical history, including a previous stroke or transient ischaemic attack, all did not predict either overall or non-procedural PLATO Major bleeding. Thus, no particular group was identified at risk for any subset of bleeding.</p><p><em>CABG-related bleeding: </em>In PLATO, 42% of the 1584 patients (12% of cohort) who underwent coronary artery bypass graft (CABG) surgery had a PLATO Major Fatal/Life-threatening bleeding with no difference between treatment groups. Fatal CABG bleeding occurred in 6 patients in each treatment group (see section 4.4).</p><p><em>Non-CABG related bleeding and non-procedural related bleeding: </em>Ticagrelor and clopidogrel did not differ in non-CABG PLATO-defined Major Fatal/Life-threatening bleeding, but PLATO-defined Total Major, TIMI Major, and TIMI Major + Minor bleeding were more common with ticagrelor.</p><p>Similarly, when removing all procedure related bleeds, more bleeding occurred with ticagrelor than with clopidogrel (Table 2). Discontinuation of treatment due to non-procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p&lt;0.001).</p><p><em>Intracranial bleeding:</em></p><p>There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients,</p><p>0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal. There was no difference in overall fatal bleeds.</p><p><em>Bleeding findings in PEGASUS</em></p><p>Overall outcome of bleeding events in the PEGASUS study are shown in Table 3.</p><p><strong>Table 3 &ndash; Analysis of overall bleeding events, Kaplan-Meier estimates at 36 months (PEGASUS)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Ticagrelor 60 mg twice daily + ASA</strong></p><p><strong>N=6958</strong></p></td><td style="vertical-align:top"><p><strong>ASA alone N=6996</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Safety Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>KM%</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>KM%</strong></p></td><td style="vertical-align:top"><p><strong><em>p</em></strong><strong>-value</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>TIMI-defined bleeding categories</strong></p></td></tr><tr><td style="vertical-align:top"><p>TIMI Major</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>2.32</p><p>(1.68, 3.21)</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Fatal</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.00</p><p>(0.44, 2.27)</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.0000</p></td></tr><tr><td style="vertical-align:top"><p>ICH</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>1.33</p><p>(0.77, 2.31)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0.3130</p></td></tr><tr><td style="vertical-align:top"><p>Other TIMI Major</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>3.61</p><p>(2.31, 5.65)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>TIMI Major or Minor</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>2.54</p><p>(1.93, 3.35)</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>TIMI Major or Minor or Requiring</p><p>medical attention</p></td><td style="vertical-align:top"><p>16.6</p></td><td style="vertical-align:top"><p>2.64</p><p>(2.35, 2.97)</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>PLATO-defined bleeding categories</strong></p></td></tr><tr><td style="vertical-align:top"><p>PLATO Major</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>2.57</p><p>(1.95, 3.37)</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Fatal/Life-threatening</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2.38</p><p>(1.73, 3.26)</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Other PLATO Major</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>3.37</p><p>(1.95, 5.83)</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>PLATO Major or Minor</p></td><td style="vertical-align:top"><p>15.2</p></td><td style="vertical-align:top"><p>2.71</p><p>(2.40, 3.08)</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>Bleeding category definitions:</p><p><strong>TIMI Major: </strong>Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of haemorrhage associated with a drop in haemoglobin (Hgb) of &ge;50 g/L, or when Hgb is not available, a fall in haematocrit (Hct) of 15%.</p><p><strong>Fatal: </strong>A bleeding event that directly led to death within 7 days.</p><p><strong>ICH: </strong>Intracranial haemorrhage.</p><p><strong>Other TIMI Major: </strong>Non-fatal non-ICH TIMI Major bleeding.</p><p><strong>TIMI Minor: </strong>Clinically apparent with 30-50 g/L decrease in haemoglobin.</p><p><strong>TIMI Requiring medical attention: </strong>Requiring intervention, OR leading to hospitalization, OR prompting evaluation.</p><p><strong>PLATO Major Fatal/life-threatening: </strong>Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolaemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent with &gt;50 g/L decrease in haemoglobin or &ge;4 red cell units transfused.</p><p><strong>PLATO Major Other: </strong>Significantly disabling, OR clinically apparent with 30-50 g/L decrease in haemoglobin, OR 2-3 red cell units transfused.</p><p><strong>PLATO Minor: </strong>Requires medical intervention to stop or treat bleeding.</p><p>In PEGASUS, TIMI Major bleeding for ticagrelor 60 mg twice daily was higher than for ASA alone. No increased bleeding risk was seen for fatal bleeding and only a minor increase was observed in intracranial haemorrhages, as compared to ASA therapy alone. There were few fatal bleeding events in the study, 11 (0.3%) for ticagrelor 60 mg and 12 (0.3%) for ASA therapy alone. The observed increased risk of TIMI Major bleeding with ticagrelor 60 mg was primarily due to a higher frequency of Other TIMI Major bleedings driven by events in the gastrointestinalSOC.</p><p>Increased bleeding patterns similar to TIMI Major were seen for TIMI Major or Minor and PLATO Major and PLATO Major or Minor bleeding categories (see Table 3). Discontinuation of treatment due to bleeding was more common with ticagrelor 60 mg compared to ASA therapy alone (6.2% and 1.5%, respectively). The majority of these bleedings were of less severity (classified as TIMI Requiring medical attention), e.g. epistaxis, bruising and haematomas.</p><p>The bleeding profile of ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy, and Medical History) for TIMI Major, TIMI Major or Minor and PLATO Major bleeding events.</p><p><em>Intracranial bleeding:</em></p><p>Spontaneous ICHs were reported in similar rates for ticagrelor 60 mg and ASA therapy alone(n=13, 0.2% in both treatment groups). Traumatic and procedural ICHs showed a minor increase with ticagrelor 60 mg treatment, (n=15, 0.2%) compared with ASA therapy alone (n=10, 0.1%). There were 6 fatal ICHs with ticagrelor 60 mg and 5 fatal ICHs with ASA therapy alone. The incidence of intracranial bleeding was low in both treatment groups given the significant comorbidity and CV risk factors of the population under study.</p><p><em>Dyspnoea</em></p><p>Dyspnoea, a sensation of breathlessness, is reported by patients treated with ticagrelor. In PLATO, dyspnoea adverse events (AEs) (dyspnoea, dyspnoea at rest, dyspnoea exertional, dyspnoea paroxysmal nocturnal and nocturnal dyspnoea), when combined, was reported by 13.8% of patients treated with ticagrelor and by 7.8% of patients treated with clopidogrel. In 2.2% of patients taking ticagrelor and by 0.6% taking clopidogrel investigators considered the dyspnoea causally related to treatment in the PLATO study and few were serious (0.14% ticagrelor; 0.02% clopidogrel), (see section 4.4). Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode early after starting treatment.</p><p>Compared with clopidogrel, patients with asthma/COPD treated with ticagrelor may have an increased risk of experiencing non-serious dyspnoea (3.29% ticagrelor versus 0.53% clopidogrel) and serious dyspnoea (0.38% ticagrelor versus 0.00% clopidogrel). In absolute terms, this risk was higher than in the overall PLATO population. Ticagrelor should be used with caution in patients with history of asthma and/or COPD (see section 4.4).</p><p>About 30% of episodes resolved within 7 days. PLATO included patients with baseline congestive heart failure, COPD, or asthma; these patients, and the elderly, were more likely to report dyspnoea. For ticagrelor, 0.9% of patients discontinued study drug because of dyspnoea compared with 0.1% taking clopidogrel. The higher incidence of dyspnoea with ticagrelor is not associated with new or worsening heart or lung disease (see section 4.4). Ticagrelor does not affect tests of pulmonary function.</p><p>In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of patients taking ASA alone. As in PLATO, most reported dyspnoea was mild to moderate in intensity (see section 4.4). Patients who reported dyspnoea tended to be older and more frequently had dyspnoea, COPD or asthma at baseline.</p><p><em>Investigations</em></p><p>Uric acid elevations: In PLATO, serum uric acid increased to more than upper limit of normal in 22% of patients receiving ticagrelor compared to 13% of patients receiving clopidogrel. The corresponding numbers in PEGASUS were 9.1%, 8.8% and 5.5% for ticagrelor 90 mg, 60 mg and placebo, respectively. Mean serum uric acid increased approximately 15% with ticagrelor compared to approximately 7.5% with clopidogrel and after treatment was stopped, decreased to approximately 7% on ticagrelor but with no decrease observed for clopidogrel. In PEGASUS, a reversible increase in mean serum uric acid levels of 6.3% and 5.6% was found for ticagrelor 90 mg and 60 mg, respectively, compared to a 1.5% decrease in the placebo group. In PLATO, the frequency of gouty arthritis was 0.2% for ticagrelor <em>vs</em>. 0.1% for clopidogrel. The corresponding numbers for gout/gouty arthritis in PEGASUS were 1.6%, 1.5% and 1.1% for ticagrelor 90 mg, 60 mg and placebo, respectively.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To reports any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong><img alt="" width="536" height="100" src="data:image/png;base64,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" /></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong><img alt="" width="815" height="44" src="data:image/png;base64,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" /></strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see section 4.8).</p><p>In the event of an overdose, the above potential adverse reactions could occur and ECG monitoring should be considered.</p><p>There is currently no known antidote to reverse the effects of ticagrelor, and ticagrelor is not expected to be dialysable (see section 4.4). Treatment of overdose should follow local standard medical practice. The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding (see section 4.4). If bleeding occurs other appropriate supportive measures should be taken.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Platelet aggregation inhibitors excluding heparin,</p><p>ATC code: B01AC24</p><p><u>Mechanism of action</u></p><p>prevents ADP- mediated P2Y12 dependent platelet activation and aggregation. Ticagrelor does not prevent ADP binding but when bound to the P2Y12 receptor prevents ADP-induced signal transduction. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function has been shown to reduce the risk of CV events such as death, MI or stroke.</p><p>Ticagrelor also increases local endogenous adenosine levels by inhibiting the equilibrative nucleoside transporter-1 (ENT-1).</p><p>Ticagrelor has been documented to augment the following adenosine-induced effects in healthy subjects and in patients with ACS: vasodilation (measured by coronary blood flow increases in healthy volunteers and ACS patients; headache), inhibition of platelet function (in human whole blood <em>in vitro</em>) and dyspnoea. However, a link between the observed increases in adenosine and clinical outcomes (e.g. morbidity-mortality) has not been clearly elucidated.</p><p><u>Pharmacodynamic effects</u></p><p><em><u>Onset of action</u></em></p><p>In patients with stable coronary artery disease (CAD) on ASA, ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean inhibition of platelet aggregation (IPA) for ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours. 90% of patients had final extent IPA</p><p>&gt;70% by 2 hours post dose.</p><p><em><u>Offset of action</u></em></p><p>If a CABG procedure is planned, ticagrelor bleeding risk is increased compared to clopidogrel when discontinued within less than 96 hours prior to procedure.</p><p><em><u>Switching data</u></em></p><p>Switching from clopidogrel 75 mg to ticagrelor 90 mg twice daily results in an absolute IPA increase of 26.4% and switching from ticagrelor to clopidogrel results in an absolute IPA decrease of 24.5%. Patients can be switched from clopidogrel to ticagrelor without anyinterruption of antiplatelet effect (see section 4.2).</p><p><u>Clinical efficacy and safety</u></p><p>The clinical evidence for the efficacy and safety of ticagrelor is derived from two phase 3 trials:</p><p>&bull;&nbsp;&nbsp;&nbsp; The PLATO [P<u>LATe</u>let Inhibition and Patient <u>O</u>utcomes] study, a comparison of ticagrelor to clopidogrel, both given in combination with ASA and other standardtherapy.</p><p>&bull;&nbsp;&nbsp; The PEGASUS TIMI-54 [<u>P</u>r<u>E</u>vention with Tica<u>G</u>relor of Second<u>A</u>ry Thrombotic Events in High- Ri<u>S</u>k Ac<u>U</u>te Coronary <u>S</u>yndrome Patients] study, a comparison of ticagrelor combined with ASA to ASA therapy alone.</p><p>PLATO study (Acute Coronary Syndromes)</p><p>The PLATO study included 18,624 patients who presented within 24 hours of onset of symptoms of unstable angina (UA), non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI), and were initially managed medically, or with percutaneous coronary intervention (PCI), or with CABG.</p><p><em><u>Clinical efficacy</u></em></p><p>On a background of daily ASA, ticagrelor 90 mg twice daily showed superiority to 75 mg daily clopidogrel in preventing the composite endpoint of CV death, MI, or stroke, with the difference</p><p>driven by CV death and MI. Patients received a 300 mg loading dose of clopidogrel (600 mg possible if having PCI) or 180 mg of ticagrelor.</p><p>The result appeared early (absolute risk reduction [ARR] 0.6% and relative risk reduction [RRR] of 12% at 30 days), with a constant treatment effect over the entire 12-month period, yielding ARR 1.9% per year with RRR of 16%. This suggests it is appropriate to treat patients with ticagrelor 90 mg twice daily for 12 months (see section 4.2). Treating 54 ACS patients with ticagrelor instead of clopidogrel will prevent 1 atherothrombotic event; treating 91 will prevent 1 CV death (see Figure 1 and Table 4).</p><p>The treatment effect of ticagrelor over clopidogrel appears consistent across many subgroups, including weight; sex; medical history of diabetes mellitus, transient ischaemic attack or non- haemorrhagic stroke, or revascularisation; concomitant therapies including heparins, GpIIb/IIIa inhibitors and proton pump inhibitors (see section 4.5); final index event diagnosis (STEMI, NSTEMI, or UA); and treatment pathway intended at randomisation (invasive or medical).</p><p>A weakly significant treatment interaction was observed with region whereby the hazard ratio (HR) for the primary endpoint favours ticagrelor in the rest of world but favours clopidogrel in North America, which represented approximately 10% of the overall population studied (interaction p- value=0.045).</p><p>Exploratory analyses suggest a possible association with ASA dose such that reduced efficacy was observed with ticagrelor with increasing ASA doses. Chronic daily ASA doses to accompany ticagrelor should be 75-150 mg (see sections 4.2 and 4.4).</p><p>Figure 1 shows the estimate of the risk to the first occurrence of any event in the composite efficacy endpoint.</p><p>Figure 1 &ndash; Analysis of primary clinical composite endpoint of CV death, MI and stroke (PLATO)</p><p><img src="data:image/jpeg;base64,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" alt="" width="528" height="266" vspace="0" hspace="0" border="0" style="width:528px;height:266px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Ticagrelor reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and STEMI population (Table 4). Thus, Ticagrelor SPC Tablets 90 mg twice daily together with low-dose ASA can be used in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).</p><p>Table 4 - Analysis of primary and secondary efficacy endpoints (PLATO)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ticagrelor 90 mg twice daily (% patients with event)</strong></p><p><strong>N=9333</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel 75 mg once daily (% patients with event) N=9291</strong></p></td><td style="vertical-align:top"><p><strong>ARRa</strong></p><p><strong>(%/yr)</strong></p></td><td style="vertical-align:top"><p><strong>RRRa (%) (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong><em>p-</em></strong><strong>value</strong></p></td></tr><tr><td style="vertical-align:top"><p>CV death, MI (excl.</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>10.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>16 ( 8, 23)</p></td><td style="vertical-align:top"><p>0.0003</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>silent MI) or stroke</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Invasive intent</p></td><td style="vertical-align:top"><p>8.5</p></td><td style="vertical-align:top"><p>10.0</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>16 ( 6, 25)</p></td><td style="vertical-align:top"><p>0.0025</p></td></tr><tr><td style="vertical-align:top"><p>Medical intent</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>13.2</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>15 (0.3, 27)</p></td><td style="vertical-align:top"><p>0.0444<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>21 ( 9, 31)</p></td><td style="vertical-align:top"><p>0.0013</p></td></tr><tr><td style="vertical-align:top"><p>MI (excl. silent MI)<sup>b</sup></p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>16 ( 5, 25)</p></td><td style="vertical-align:top"><p>0.0045</p></td></tr><tr><td style="vertical-align:top"><p>Stroke</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>-0.2</p></td><td style="vertical-align:top"><p>-17 (-52, 9)</p></td><td style="vertical-align:top"><p>0.2249</p></td></tr><tr><td style="vertical-align:top"><p>All-cause&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mortality,</p><p>MI (excl. silent MI), or stroke</p></td><td style="vertical-align:top"><p>9.7</p></td><td style="vertical-align:top"><p>11.5</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>16 ( 8, 23)</p></td><td style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p>CV death, total MI,</p><p>stroke, SRI, RI, TIA, or other ATE<sup>c</sup></p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>15.7</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>12 ( 5, 19)</p></td><td style="vertical-align:top"><p>0.0006</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>22 (11, 31)</p></td><td style="vertical-align:top"><p>0.0003<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Definite&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stent</p><p>thrombosis</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>32 ( 8, 49)</p></td><td style="vertical-align:top"><p>0.0123<sup>d</sup></p></td></tr></tbody></table><p><sup>a</sup>ARR = absolute risk reduction; RRR = relative risk reduction = (1-Hazard ratio) x 100%. A negative RRR indicates a relative risk increase.</p><p><sup>b</sup>Excluding silent MI.</p><p><sup>c</sup>SRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE</p><p>= arterial thrombotic event. Total MI includes silent MI, with date of event set to date when discovered.</p><p><sup>d</sup>Nominal significance value; all others are formally statistically significant by pre-defined hierarchical testing.</p><p><u>PLATO genetic substudy</u></p><p>CYP2C19 and ABCB1 genotyping of 10,285 patients in PLATO provided associations of genotype groups with PLATO outcomes. The superiority of ticagrelor over clopidogrel in reducing major CV events was not significantly affected by patient CYP2C19 or ABCB1 genotype. Similar to the overall PLATO study, total PLATO Major bleeding did not differ between ticagrelor and clopidogrel, regardless of CYP2C19 or ABCB1 genotype. Non-CABG PLATO Major bleeding was increased with ticagrelor compared clopidogrel in patients with one or more CYP2C19 loss of function alleles, but similar to clopidogrel in patients with no loss of function allele.</p><p><u>Combined efficacy and safety composite</u></p><p>A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined &#39;Total Major&#39; bleeding) indicates that the benefit in efficacy of ticagrelor compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS. <em><u>Clinical safety</u></em></p><p><em><u>Holter Substudy</u></em></p><p>To study the occurrence of ventricular pauses and other arrhythmic episodes during PLATO, investigators performed Holter monitoring in a subset of nearly 3000 patients, of whom approximately 2000 had recordings both in the acute phase of their ACS and after one month. The primary variable of interest was the occurrence of ventricular pauses &ge;3 seconds. More patients had ventricular pauses with ticagrelor (6.0%) than with clopidogrel (3.5%) in the acute phase; and 2.2% and 1.6% respectively after 1 month (see section 4.4). The increase in ventricular pauses in the acute phase of ACS was more pronounced in ticagrelor patients with history of CHF (9.2% versus 5.4% in patients without CHF history; for clopidogrel patients, 4.0% in those with versus 3.6% in those without CHF history) This imbalance did not occur at one month: 2.0% versus 2.1% for ticagrelor patients with and without CHF history respectively; and 3.8% versus 1.4% with clopidogrel. There were no adverse clinical consequences associated with this imbalance (including pacemaker insertions) in this population of patients.</p><p>PEGASUS study (History of Myocardial Infarction)</p><p>The PEGASUS TIMI-54 study was a 21,162 patients, event-driven, randomised, double-blind, placebo-controlled, parallel group, international multicentre study to assess the prevention of atherothrombotic events with ticagrelor given at 2 doses (either 90 mg twice daily or 60 mg twice daily) combined with low dose ASA (75-150 mg), compared to ASA therapy alone in patients with history of MI and additional risk factors for atherothrombosis.</p><p>Patients were eligible to participate if they were aged 50 years or over, with a history of MI (1 to 3 years prior to randomisation), and had at least one of the following risk factors for atherothrombosis: age &ge;65 years, diabetes mellitus requiring medication, a second prior MI, evidence of multivessel CAD, or chronic non-end-stage renal dysfunction.</p><p>Patients were ineligible if there was planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour, or an</p><p>intracranial vascular abnormality; if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days.</p><p><em><u>Clinical efficacy</u></em></p><p>Figure 2 - Analysis of primary clinical composite endpoint of CV death, MI and stroke (PEGASUS)</p><p><img src="data:image/jpeg;base64,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" alt="" width="559" height="331" vspace="0" hspace="0" border="0" style="width:559px;height:331px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Table 5 - Analysis of primary and secondary efficacy endpoints (PEGASUS)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Ticagrelor 60 mg twice daily +ASA</strong></p><p><strong>N = 7045</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ASA alone</strong></p><p><strong>N = 7067</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>p</em></strong><strong>-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Characteristic</strong></p></td><td style="vertical-align:top"><p><strong>Patients with events</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>KM %</strong></p></td><td style="vertical-align:top"><p><strong>HR </strong><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Patients </strong><strong>with</strong></p><p><strong>events</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>KM %</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Primary endpoint</p></td></tr><tr><td style="vertical-align:top"><p>Composite&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp; CV</p></td><td rowspan="2" style="vertical-align:top"><p>487 (6.9%)</p></td><td rowspan="2" style="vertical-align:top"><p>7.8%</p></td><td style="vertical-align:top"><p>0.84</p></td><td style="vertical-align:top"><p>578</p></td><td rowspan="2" style="vertical-align:top"><p>9.0%</p></td><td rowspan="2" style="vertical-align:top"><p>0.0043 (s)</p></td></tr><tr><td style="vertical-align:top"><p>Death/MI /Stroke</p></td><td style="vertical-align:top"><p>(0.74, 0.95)</p></td><td style="vertical-align:top"><p>(8.2%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>CV death</p></td><td rowspan="2" style="vertical-align:top"><p>174 (2.5%)</p></td><td rowspan="2" style="vertical-align:top"><p>2.9%</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>210</p></td><td rowspan="2" style="vertical-align:top"><p>3.4%</p></td><td rowspan="2" style="vertical-align:top"><p>0.0676</p></td></tr><tr><td style="vertical-align:top"><p>(0.68, 1.01)</p></td><td style="vertical-align:top"><p>(3.0%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>MI</p></td><td rowspan="2" style="vertical-align:top"><p>285 (4.0%)</p></td><td rowspan="2" style="vertical-align:top"><p>4.5%</p></td><td style="vertical-align:top"><p>0.84</p></td><td style="vertical-align:top"><p>338</p></td><td rowspan="2" style="vertical-align:top"><p>5.2%</p></td><td rowspan="2" style="vertical-align:top"><p>0.0314</p></td></tr><tr><td style="vertical-align:top"><p>(0.72, 0.98)</p></td><td style="vertical-align:top"><p>(4.8%)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Stroke</p></td><td style="vertical-align:top"><p>91 (1.3%)</p></td><td style="vertical-align:top"><p>1.5%</p></td><td style="vertical-align:top"><p>0.75</p><p>(0.57, 0.98)</p></td><td style="vertical-align:top"><p>122</p><p>(1.7%)</p></td><td style="vertical-align:top"><p>1.9%</p></td><td style="vertical-align:top"><p>0.0337</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Secondary endpoint</p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>174 (2.5%)</p></td><td style="vertical-align:top"><p>2.9%</p></td><td style="vertical-align:top"><p>0.83</p><p>(0.68, 1.01)</p></td><td style="vertical-align:top"><p>210</p><p>(3.0%)</p></td><td style="vertical-align:top"><p>3.4%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>289 (4.1%)</p></td><td style="vertical-align:top"><p>4.7%</p></td><td style="vertical-align:top"><p>0.89</p><p>(0.76, 1.04)</p></td><td style="vertical-align:top"><p>326</p><p>(4.6%)</p></td><td style="vertical-align:top"><p>5.2%</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p>Hazard ratio and <em>p</em>-values are calculated separately for ticagrelor vs. ASA therapy alone from Cox proportional hazards model with treatment group as the only explanatory variable.</p><p>KM percentage calculated at 36 months.</p><p>Note: the number of first events for the components CV death, MI and stroke are the actual number of first events for each component and do not add up to the number of events in the composite endpoint</p><p>(s) Indicates statistical significance.</p><p>CI = Confidence interval; CV = Cardiovascular; HR = Hazard ratio; KM = Kaplan-Meier; MI = Myocardial infarction; N = Number of patients.</p><p>Both 60 mg twice daily and 90 mg twice daily regimens of ticagrelor in combination with ASA were superior to ASA alone in the prevention of atherothrombotic events (composite endpoint: CV death, MI and stroke), with a consistent treatment effect over the entire study period, yielding a 16% RRR and 1.27% ARR for ticagrelor 60 mg and a 15% RRR and 1.19% ARR for ticagrelor 90 mg.</p><p>Although the efficacy profiles of 90 mg and 60 mg were similar, there is evidence that the lower dose has a better tolerability and safety profile in relation to risk of the bleeding and dyspnoea. Therefore, only Ticagrelor SPC Tablets 60 mg twice daily co-administered with ASA is recommended for the prevention atherothrombotic events (CV death, MI and stroke) in patients with a history of MI and a high risk of developing an atherothrombotic event.</p><p>Relative to ASA alone, ticagrelor 60 mg twice daily significantly reduced the primary composite endpoint of CV death, MI and stroke. Each of the components contributed to the reduction in the primary composite endpoint (CV death 17% RRR, MI 16% RRR, and stroke 25% RRR).</p><p>The RRR for the composite endpoint from 1 to 360 days (17% RRR) and from 361 days and onwards (16% RRR) was similar. There are limited data on the efficacy and safety of ticagrelor beyond 3 years of extended treatment.</p><p>There was no evidence of benefit (no reduction in the primary composite endpoint of CV death, MI and stroke, but an increase in major bleeding) when ticagrelor 60 mg twice daily was introduced in clinically stable patients &gt;2 years from the MI, or more than one year after stopping previous ADP receptor inhibitor treatment (see also section 4.2).</p><p><em><u>Clinical safety</u></em></p><p>The rate of discontinuations with ticagrelor 60 mg due to bleeding and dyspnoea was higher in patients &gt;75 years (42%) than in younger patients (range: 23-31%), with a differenceversus placebo higher than 10% (42% vs. 29%) in patients &gt;75 years.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Ticagrelor SPC Tablets in all subsets of the paediatric population in acute coronary syndromes (ACS) and history of myocardial infarction (MI) (see section 4.2 for information on paediatricuse).&nbsp;</p><p>Ticagrelor demonstrates linear pharmacokinetics and exposure to ticagrelor and the active metabolite (AR-C124910XX) are approximately dose proportional up to 1260 mg.</p><p><u>Absorption</u></p><p>Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours. The formation of the major circulating metabolite AR-C124910XX (also active) from ticagrelor is rapid with a median tmax of approximately 2.5 hours. Following an oral ticagrelor 90 mg single dose under fasted conditions in healthy subjects, Cmax is 529 ng/ml and AUC is 3451 ng*h/ml. The metabolite parent ratios are</p><p>0.28 for Cmax and 0.42 for AUC. The pharmacokinetics of ticagrelor and AR- C124910XX in patients with a history of MI were generally similar to that in the ACS population. Based on a population pharmacokinetic analysis of the PEGASUS study the median ticagrelor Cmax was 391 ng/ml and AUC was 3801 ng*h/ml at steady state for ticagrelor 60 mg. For ticagrelor 90 mg Cmax was 627 ng/ml and AUC was 6255 ng*h/ml at steadystate.</p><p>The mean absolute bioavailability of ticagrelor was estimated to be 36%. Ingestion of a high-fat meal resulted in a 21% increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax but had no effect on ticagrelor Cmax or the AUC of the active metabolite. These small changes are considered of minimal clinical significance; therefore, ticagrelor can be given with or without food. Ticagrelor as well as the active metabolite are P-gp substrates.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor as crushed tablets mixed in water, given orally or administered through a nasogastrictube into the stomach, has a comparable bioavailability to whole tablets with regards to AUC and Cmax for ticagrelor and the active metabolite. Initial exposure (0.5 and 1 hour post-dose) from crushed ticagrelor tablets mixed in water was higher compared to whole tablets, with a generally identical concentration profile thereafter (2 to 48 hours).</p><p><u>Distribution</u></p><p>The steady state volume of distribution of ticagrelor is 87.5 l. Ticagrelor and the active metabolite is extensively bound to human plasma protein (&gt;99.0%).</p><p><u>Biotransformation</u></p><p>CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition.</p><p>The major metabolite of ticagrelor is AR-C124910XX, which is also active as assessed by <em>in vitro </em>binding to the platelet P2Y12ADP-receptor. The systemic exposure to the active metabolite is approximately 30-40% of that obtained for ticagrelor.</p><p><u>Elimination</u></p><p>The primary route of ticagrelor elimination is via hepatic metabolism. When radiolabelled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (57.8% in faeces, 26.5% in urine). Recoveries of ticagrelor and the active metabolite in urine were both less than 1% of the dose. The primary route of elimination for the active metabolite is most likely via biliary secretion. The mean t1/2 was approximately 7 hours for ticagrelor and 8.5 hours for the active metabolite.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Higher exposures to ticagrelor (approximately 25% for both Cmax and AUC) and the active metabolite were observed in elderly (&ge;75years) ACS patients compared to younger patients by the population pharmacokinetic analysis. These differences are not considered clinically significant (see section 4.2). <em>Paediatric population</em></p><p>Ticagrelor has not been evaluated in a paediatric population (see sections 4.2 and 5.1).</p><p><em>Gender</em></p><p>Higher exposures to ticagrelor and the active metabolite were observed in women compared to men. These differences are not considered clinically significant.</p><p><em>Renal impairment</em></p><p>Exposure to ticagrelor was approximately 20% lower and exposure to the active metabolite was approximately 17% higher in patients with severe renal impairment (creatinine clearance &lt;30 ml/min) compared to subjects with normal renal function .</p><p>In patients with end stage renal disease on haemodialysis AUC and Cmax of ticagrelor 90mg administrated on a day without dialysis where 38% and 51% higher compared to subjects with normal renal fnction. A similar increase in exposer was observed when ticagrelor was administrated immediately prior to dialysis (49% and 61%, respectively) showing that ticagrelor is not dialysable. Exposure to active metabolite 1 increased to lesser extent (AUC 13-14% and Cmax 17-36%). The inhibition of platelet aggregation (IPA) effect of ticagrelor was independent of dialysis in patients with end stage renal disease and similar to subjects with normal renal function (see section 4.2).</p><p><em>Hepatic impairment</em></p><p>Cmax and AUC for ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared to matched healthy subjects, respectively, however, the IPA effect of ticagrelor was similar between the two groups. No dose adjustment is needed for patients with mild hepatic impairment. Ticagrelor has not been studied in patients with severe hepatic impairment and there is no pharmacokinetic information in patients with moderate hepatic impairment. In patients that had moderate or severe elevation in one or more liver function tests at baseline, ticagrelor plasma concentrations were on average similar or slightly higher as compared to those without baseline elevations. No dose adjustment is recommended in patients with moderate hepatic impairment (see sections 4.2 and 4.4).</p><p><em>Ethnicity</em></p><p>Patients of Asian descent have a 39% higher mean bioavailability compared to Caucasian patients. Patients self-identified as black had an 18% lower bioavailability of ticagrelor compared to Caucasian patients, in clinical pharmacology studies, the exposure (Cmax and AUC) to ticagrelor in Japanese subjects was approximately 40% (20% after adjusting for body weight) higher compared to that in Caucasians. The exposure in patients self-identified as Hispanic or Latino was similar to that in Caucasians.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data for ticagrelor and its major metabolite have not demonstrated unacceptable risk for adverse effects for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxic potential.</p><p>Gastrointestinal irritation was observed in several animal species at clinical relevant exposure levels (see section 4.8).</p><p>In female rats, ticagrelor at high dose showed an increased incidence of uterine tumours (adenocarcinomas) and an increased incidence of hepatic adenomas. The mechanism for uterine tumours is likely hormonal imbalance which can lead to tumours in rats. The mechanism for the hepatic adenomas is likely due to a rodent-specific enzyme induction in the liver. Thus, the carcinogenicity findings are considered unlikely to be relevant for humans.</p><p>In rats, minor developmental anomalies were seen at a maternal toxic dose (safety margin of 5.1). In rabbits a slight delay in hepatic maturity and skeletal development was seen in foetuses from dams at high dose without showing maternal toxicity (safety margin of 4.5).</p><p>Studies in rats and rabbits have shown reproductive toxicity, with slightly reduced maternal body weight gain and reduced neonatal viability and birth weight, with delayed growth. Ticagrelor produced irregular cycles (mostly extended cycles) in female rats, but did not affect overall fertility in male and female rats. Pharmacokinetic studies performed with radio-labelled ticagrelor have shown that the parent compound and its metabolites are excreted in the milk of rats (see section 4.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ticagrelor SPC Tablets 60 mg &amp; 90 mg-</u> <u>Film Coated Tablet.</u></p><p><u>Tablet Core:</u></p><p>Mannitol , Croscarmellose sodium, Hydroxypropyl cellulose, Purified water, Dicalcium phosphate Dihydrate, Magnesium stearate.</p><p><u>Tablet Coating:</u></p><p>Opadry yellow 03B520168</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C. Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ticagrelor Tablets 60 mg</p><p>30 Count PVC/PVDC/Aluminium Blister Pack</p><p>Ticagrelor Tablets 90 mg</p><p>30 Count PVC/PVDC/Aluminium Blister Pack</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	MARKETING AUTHORIZATION HOLDER
Sudair Pharma Company (SPC)
King Fahd Rd, Al Mohammadiyah Dist. Building No. 8006, P.O. Box 12363 Riyadh, 4432, 4th Floor, Office No. 32 Saudi Arabia

8.	MANUFACTURER
MSN LABORATORIES PRIVATE LIMITED,
Formulations Division, Unit-II, Survey Nos. 1277 & 1319 to 1324, Nandigama (Village & Mandal),
Rangareddy District, Telangana 509228, India
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>